To fund its endeavours to carry MDMA therapy to market, MAPS Public Gain Company (PBC) — MAPS’ pharma subsidiary, which bifurcated in 2014 but did not acknowledge investment in return for fairness and will not safe the $70 million needed to move forward — has morphed to the for-revenue Lykos Therapeutics.1 nameless vendor said … Read More